MedTrace Logo

Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer

NCT03636893 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2025-07-23

Study results available
· View outcomes & findings →

Summary

Safety and efficacy study of neoadjuvant chemotherapy (FLOT versus SOX) for gastric cancer patients in high volume center of China

Conditions

Interventions

DRUG

FLOT Chemotherapy

5-FU+Leucovorin+Docetaxel+Oxaliplatin

DRUG

SOX Chemotherapy

Oxaliplatin+Tegafur gimeracil oteracil potassium capsule (TGO)

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Birendra Kumar Sah, PH D · Ruijin Hospital

  • Chen Li, PH D · Ruijin Hospital

  • Zhenggang Zhu, PH D · Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-24
Primary Completion
2020-03-31
Completion
2025-05-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03636893 on ClinicalTrials.gov